Bayer Gets China Approval for HER2 Lung Cancer Drug
China's regulator authorized sevabertinib as a first-line treatment for HER2-mutant non-small cell lung cancer.
Updated on Nov. 5, 2026 in Cancer
China's National Medical Products Administration granted marketing authorization for Bayer's sevabertinib as a first-line therapy for advanced HER2-mutant non-small cell lung cancer. The approval follows a related U.S. FDA accelerated approval for the same first-line use in September 2026.
Why it matters
Activating HER2 mutations are found in only 2% to 4% of patients with advanced NSCLC, so a targeted oral option for this group addresses a small but clinically distinct population. The approval extends sevabertinib's regulatory footprint across major markets, following earlier authorizations in Japan and China for previously treated patients.
The approval rests on a single-arm phase I/II cohort of 73 treatment-naive patients, which reported a 75% objective response rate with 6% complete and 70% partial responses. Whether these early response rates translate into longer survival will depend on results from the ongoing phase III SOHO-02 trial, which has not yet reported.
The players
Bayer
Bayer is a German multinational pharmaceutical and life sciences company that develops and markets prescription medicines worldwide.
National Medical Products Administration
The National Medical Products Administration is China's national regulator responsible for approving drugs and medical products for sale in the country.
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is the federal agency responsible for approving drugs and medical devices for sale in the United States.
The details
Sevabertinib is an oral, reversible small-molecule tyrosine kinase inhibitor that blocks HER2 activating mutations, including HER2 exon 20 insertions and point mutations. Earlier in 2026 China approved it as monotherapy for patients who had received one prior systemic therapy, and Japan's Ministry of Health, Labour, and Welfare approved it in August.
Timeline
Earlier in 2026: China approves sevabertinib for previously treated HER2-mutant NSCLC.
August 2026: Japan's Ministry of Health, Labour, and Welfare approves sevabertinib.
September 2026: U.S. FDA grants accelerated approval for first-line use.
November 5, 2026: Bayer announces China's first-line marketing authorization.
Big Picture
Sevabertinib joins a small class of drugs targeting HER2 mutations in lung cancer, a niche where earlier options were limited to later lines of therapy. Its first-line authorizations in China and the United States move that targeted approach earlier in treatment for the roughly 2% to 4% of advanced NSCLC patients with these mutations.
For patients with HER2-mutant NSCLC, an oral targeted option may offer an alternative to chemotherapy-based first-line regimens. Access will depend on regional approvals, reimbursement, and whether treating oncologists order HER2 mutation testing for their patients.
The takeaway
Patients diagnosed with advanced lung cancer may benefit from asking their oncologist whether HER2 mutation testing has been performed. Testing can identify candidates for targeted therapies like sevabertinib.
Further reading
Explore more on Cancer treatments and research.
